TY - JOUR
TI - Chronic hepatitis B and C virus infection and risk for non-hodgkin lymphoma in HIV-infected patients: A cohort study
AU - Wang, Q.
AU - De Luca, A.
AU - Smith, C.
AU - Zangerle, R.
AU - Sambatakou, H.
AU - Bonnet, F.
AU - Smit, C.
AU - Schommers, P.
AU - Thornton, A.
AU - Berenguer, J.
AU - Peters, L.
AU - Spagnuolo, V.
AU - Ammassari, A.
AU - Antinori, A.
AU - Roldan, E.Q.
AU - Mussini, C.
AU - Miro, J.M.
AU - Konopnicki, D.
AU - Fehr, J.
AU - Campbell, M.A.
AU - Termote, M.
AU - Bucher, H.C.
AU - De Wit, S.
AU - Costagliola, D.
AU - D'Arminio-Monforte, A.
AU - Castagna, A.
AU - Del Amo, J.
AU - Mocroft, A.
AU - Raben, D.
AU - Chêne, G.
AU - Touloumi, G.
AU - Warszawski, J.
AU - Meyer, L.
AU - Dabis, F.
AU - Krause, M.M.
AU - Ghosn, J.
AU - Leport, C.
AU - Wittkop, L.
AU - Reiss, P.
AU - Wit, F.
AU - Prins, M.
AU - Sabin, C.
AU - Gibb, D.
AU - Fätkenheuer, G.
AU - Obel, N.
AU - Thorne, C.
AU - Kirk, O.
AU - Stephan, C.
AU - Pérez-Hoyos, S.
AU - Hamouda, O.
AU - Bartmeyer, B.
AU - Chkhartishvili, N.
AU - Noguera-Julian, A.
AU - Brockmeyer, N.
AU - Prieto, L.
AU - Conejo, P.R.
AU - Soriano-Arandes, A.
AU - Battegay, M.
AU - Rauch, A.
AU - Tookey, P.
AU - Casabona, J.
AU - Goetghebuer, T.
AU - Sönnerborg, A.
AU - Torti, C.
AU - Teira, R.
AU - Garrido, M.
AU - Haerry, D.
AU - Bohlius, J.
AU - Bouteloup, V.
AU - Cozzi-Lepri, A.
AU - Davies, M.-A.
AU - Dorrucci, M.
AU - Dunn, D.
AU - Egger, M.
AU - Furrer, H.
AU - Guiguet, M.
AU - Grabar, S.
AU - Judd, A.
AU - Lambotte, O.
AU - Leroy, V.
AU - Lodi, S.
AU - Matheron, S.
AU - Monge, S.
AU - Nakagawa, F.
AU - Paredes, R.
AU - Phillips, A.
AU - Puoti, M.
AU - Schomaker, M.
AU - Sterne, J.
AU - Thiebaut, R.
AU - Van Der Valk, M.
AU - Wyss, N.
AU - Barger, D.
AU - Schwimmer, C.
AU - Friis-Møller, N.
AU - Kjaer, J.
AU - Brandt, R.S.
AU - The Hepatitis Coinfection
AU - Non Hodgkin Lymphoma project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord
JO - ANNALS OF INTERNAL MEDICINE
PY - 2017
VL - 166
TODO - 1
SP - 9-17
PB - American College of Physicians
SN - 0003-4819
TODO - 10.7326/M16-0240
TODO - anti human immunodeficiency virus agent;  biological marker;  hepatitis antibody;  hepatitis B core antigen;  hepatitis B surface antigen;  immunoglobulin G;  virus RNA, adult;  antiretroviral therapy;  Article;  brain lymphoma;  Burkitt lymphoma;  cancer incidence;  cancer risk;  chronic hepatitis B;  chronic hepatitis C;  controlled study;  diffuse large B cell lymphoma;  disease association;  female;  follow up;  human;  Human immunodeficiency virus infected patient;  Human immunodeficiency virus infection;  major clinical study;  male;  nonhodgkin lymphoma;  priority journal;  blood;  cohort analysis;  complication;  Hepatitis B, Chronic;  hepatitis C;  Hepatitis C, Chronic;  HIV Infections;  immunology;  mortality;  nonhodgkin lymphoma;  risk factor, Adult;  Anti-HIV Agents;  Biomarkers;  Cohort Studies;  Female;  Hepatitis Antibodies;  Hepatitis B Core Antigens;  Hepatitis B Surface Antigens;  Hepatitis B, Chronic;  Hepatitis C;  Hepatitis C, Chronic;  HIV Infections;  Humans;  Immunoglobulin G;  Lymphoma, Non-Hodgkin;  Male;  Risk Factors;  RNA, Viral
TODO - Background: Non-Hodgkin lymphoma (NHL) is the most common AIDS-defining condition in the era of antiretroviral therapy (ART). Whether chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection promote NHL in HIV-infected patients is unclear. Objective: To investigate whether chronic HBV and HCV infection are associated with increased incidence of NHL in HIVinfected patients. Design: Cohort study. Setting: 18 of 33 cohorts from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). Patients: HIV-infected patients with information on HBV surface antigen measurements and detectable HCV RNA, or a positive HCV antibody test result if HCV RNA measurements were not available. Measurements: Time-dependent Cox models to assess risk for NHL in treatment-naive patients and those initiating ART, with inverse probability weighting to control for informative censoring. Results: A total of 52 479 treatment-naive patients (1339 [2.6%] with chronic HBV infection and 7506 [14.3%] with HCV infection) were included, of whom 40 219 (77%) later started ART. The median follow-up was 13 months for treatment-naive patients and 50 months for those receiving ART. A total of 252 treatmentnaive patients and 310 treated patients developed NHL, with incidence rates of 219 and 168 cases per 100 000 person-years, respectively. The hazard ratios for NHL with HBV and HCV infection were 1.33 (95% CI, 0.69 to 2.56) and 0.67 (CI, 0.40 to 1.12), respectively, in treatment-naive patients and 1.74 (CI, 1.08 to 2.82) and 1.73 (CI, 1.21 to 2.46), respectively, in treated patients. Limitation: Many treatment-naive patients later initiated ART, which limited the study of the associations of chronic HBV and HCV infection with NHL in this patient group. Conclusion: In HIV-infected patients receiving ART, chronic coinfection with HBV and HCV is associated with an increased risk for NHL. © 2017 American College of Physicians.
ER -